Switch theme
Sign up to access all valuation multiples
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
2014
403
LTM Revenue $55.5M
LTM EBITDA -$497M
$385M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Intellia Therapeutics has a last 12-month revenue of $55.5M and a last 12-month EBITDA of -$497M.
In the most recent fiscal year, Intellia Therapeutics achieved revenue of $57.9M and an EBITDA of -$524M.
Intellia Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Intellia Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $36.3M | $57.9M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$506M | -$524M | XXX | XXX | XXX |
| EBITDA Margin | -1396% | -905% | XXX | XXX | XXX |
| Net Profit | -$474M | -$481M | XXX | XXX | XXX |
| Net Margin | -1307% | -831% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Intellia Therapeutics's stock price is $8.
Intellia Therapeutics has current market cap of $776M, and EV of $385M.
See Intellia Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $385M | $776M | XXX | XXX | XXX | XXX | $-5.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Intellia Therapeutics has market cap of $776M and EV of $385M.
Intellia Therapeutics's trades at 6.9x LTM EV/Revenue multiple, and -0.8x LTM EBITDA.
Analysts estimate Intellia Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Intellia Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $385M | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | XXX | XXX |
| P/E | -1.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIntellia Therapeutics's NTM/LTM revenue growth is -14%
Intellia Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.5M for the same period.
Over next 12 months, Intellia Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Intellia Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Intellia Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 60% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -905% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -920% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 217% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 806% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1023% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Intellia Therapeutics acquired XXX companies to date.
Last acquisition by Intellia Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Intellia Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Intellia Therapeutics founded? | Intellia Therapeutics was founded in 2014. |
| Where is Intellia Therapeutics headquartered? | Intellia Therapeutics is headquartered in United States of America. |
| How many employees does Intellia Therapeutics have? | As of today, Intellia Therapeutics has 403 employees. |
| Who is the CEO of Intellia Therapeutics? | Intellia Therapeutics's CEO is Dr. John M. Leonard, M.D.. |
| Is Intellia Therapeutics publicy listed? | Yes, Intellia Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Intellia Therapeutics? | Intellia Therapeutics trades under NTLA ticker. |
| When did Intellia Therapeutics go public? | Intellia Therapeutics went public in 2016. |
| Who are competitors of Intellia Therapeutics? | Similar companies to Intellia Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Intellia Therapeutics? | Intellia Therapeutics's current market cap is $776M |
| What is the current revenue of Intellia Therapeutics? | Intellia Therapeutics's last 12-month revenue is $55.5M. |
| What is the current EBITDA of Intellia Therapeutics? | Intellia Therapeutics's last 12-month EBITDA is -$497M. |
| What is the current EV/Revenue multiple of Intellia Therapeutics? | Current revenue multiple of Intellia Therapeutics is 6.9x. |
| What is the current EV/EBITDA multiple of Intellia Therapeutics? | Current EBITDA multiple of Intellia Therapeutics is -0.8x. |
| What is the current revenue growth of Intellia Therapeutics? | Intellia Therapeutics revenue growth between 2023 and 2024 was 60%. |
| Is Intellia Therapeutics profitable? | Yes, Intellia Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
